Peptide Schedule
OrforglipronSmall moleculeNo amino acid sequence. Icon reflects category theme only.Orforglipron Dosage Calculator
Orforglipron (brand name Foundayo) is the first oral non-peptide GLP-1 receptor agonist — and that distinction matters.
5.5mcg · Daily
Summary: Add 0mL BAC water to your 45mg vial. Draw to < 0.1 units on a U-100 syringe for a 5.5mcg dose. This vial will last 0 doses.
Cycle Planner
Orforglipron Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~29-68 hoursDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Orforglipron Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 5.5mg | Daily |
| Moderate | 14.5mg | Daily |
| Aggressive | 17.2mg | Daily |
Note: Oral tablet — no injection, no reconstitution. Brand name Foundayo. FDA-approved April 2026. Titrate from 0.8mg daily: 0.8mg x 30 days, then 2.5mg x 30 days, then 5.5mg x 30 days, then increase to 9mg, 14.5mg, or 17.2mg based on response. Take with or without food — no water or fasting restrictions.
About Orforglipron
Orforglipron (brand name Foundayo) is the first oral non-peptide GLP-1 receptor agonist — and that distinction matters. Unlike semaglutide, tirzepatide, and every other GLP-1 drug on the market, it isn't a peptide at all. It's a small-molecule compound built on a rigid polycyclic heteroaromatic scaffold, which means it survives stomach acid and absorbs through the gut without the enteric coatings or absorption enhancers that oral semaglutide (Rybelsus) requires. You can take it any time of day, with or without food, with no water restrictions. Eli Lilly developed orforglipron (originally LY3502970/OWL-833) and received FDA approval on April 1, 2026 — just 50 days after filing the NDA, making it the fastest approval of a new molecular entity since 2002. It was the fifth drug approved under the FDA's National Priority Voucher program. In the ATTAIN-1 trial (3,127 adults with obesity but without diabetes), the highest dose produced an average weight loss of 27.3 lbs (12.4%) over 72 weeks versus 2.2 lbs (0.9%) with placebo. The ATTAIN-2 trial confirmed similar efficacy in people with type 2 diabetes. And in the head-to-head ACHIEVE-3 trial, orforglipron 36mg beat oral semaglutide 14mg for both HbA1c reduction and weight loss — though it's worth noting the ORION indirect comparison found higher-dose oral semaglutide (25mg) may edge ahead on pure weight loss. The GI side effect profile is typical for GLP-1 drugs — nausea, vomiting, diarrhea — and discontinuation rates due to GI events were higher than injectable options. But for millions of people who won't use needles, an effective oral option at $149/month self-pay changes the accessibility equation entirely.